Since CSCs are currently considered as a major source of tumor recurrence [18,25,26], MEK1/2-related promotion of cancer cell stemness could possibly underlie a failure of several clinical trials focused on trametinib alone or as a part of complex anti-tumor therapy [83,84]. The gene discussed is MAP2K1; the disease is neoplasm.